Danazol Pill
Phase 2Small molecule
Danazol Pill is one of 49 small molecule programs targeting Cirrhosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Xifaxan
SSalix
Approved
Zocor
OOrganon and Co
Approved
Chronulac
SSolvay Pharmaceuticals
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Esmeron
FFresenius Kabi USA, LLC
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bumex
VValidus Pharmaceuticals
Phase 3
Crestor
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Complication1 trial
PRETELL: PREvention of TELomere-related Complications After Lung Transplant
Withdrawn·—·Phase 1/2·NCT04807309
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Danazol Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details